Skip to main content
Clinical Trials/NCT01475929
NCT01475929
Terminated
Phase 2

Effect of Probiotic Supplement on Bowel Function

Danisco1 site in 1 country149 target enrollmentJune 2011

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Irritable Bowel Syndrome
Sponsor
Danisco
Enrollment
149
Locations
1
Primary Endpoint
Change in functional bowel symptoms
Status
Terminated
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this study is to analyse the effect of probiotic supplement on symptoms of irritable bowel syndrome.

Detailed Description

The aim of the intervention is to analyse the effect of a probiotic supplement in a dose-responsive set up on symptoms of irritable bowel syndrome (IBS). Fulfillment of Rome III criteria will be used as inclusion criterion. Subjective assessment of bowel symptoms, IBS-related quality of life and adequate relief will be assessed as outcome measures.

Registry
clinicaltrials.gov
Start Date
June 2011
End Date
May 2012
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Danisco
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects aged 18 to 65 with functional bowel symptoms and fulfilling Rome III criteria for IBS will be recruited. Sufficient general health and orientation for participating in the study is required and will be evaluated by the MDs.

Exclusion Criteria

  • Diagnosed or suspected organic gastrointestinal diseases or severely impaired general health are exclusion criteria.

Outcomes

Primary Outcomes

Change in functional bowel symptoms

Time Frame: 0 weeks, 6 weeks, 12 weeks

Validated questionnaire

Secondary Outcomes

  • Adequate relief(Weekly over 3 month intervention)
  • Change in faecal microbiota(0 weeks, 6 weeks, 12 weeks)
  • Change in quality of life(0 weeks, 6 weeks, 12 weeks)

Study Sites (1)

Loading locations...

Similar Trials